Innovations and challenges in renal cancer: Consensus statement from the first international conference

Michael B. Atkins, David E. Avigan, Ronald M. Bukowski, Richard W. Childs, Janice P. Dutcher, Tim G. Eisen, Robert A. Figlin, James H. Finke, Robert C. Flanigan, Daniel J. George, S. Nahum Goldberg, Michael S. Gordon, Othon Iliopoulos, William G. Kaelin, W. Marston Linehan, Allan Lipton, Robert J. Motzer, Andrew C. Novick, Walter M. Stadler, Bin Tean TehJames C. Yang, Laura King

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Renal cell carcinoma is a serious medical problem in the United States, with nearly 35,000 new cases and >12,000 cancer-related deaths reported in 2003 (21). A number exciting advances in understanding the genetics, biology, and prognostic and predictive factors for renal cell carcinoma, as well as better local therapies, are improving the outlook for patients with advanced renal cell carcinoma. Although combinations of various treatment approaches might produce synergistic antitumor activity, we lack the mechanisms to rapidly and efficiently identify potentially effective combinations. Good surrogates of biological effect are needed to efficiently study strategies for combining various approaches. Nonetheless, for the first time in many years, investigators are primed to make significant advances in the treatment of renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)6277s-6281s
JournalClinical Cancer Research
Issue number18 II
StatePublished - Sep 15 2004

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Innovations and challenges in renal cancer: Consensus statement from the first international conference'. Together they form a unique fingerprint.

Cite this